Stockscreener 앱 받기
12.06
3.79%
0.44
시간 외 거래:
12.09
0.03
+0.25%
전일 마감가:
$11.62
열려 있는:
$11.76
하루 거래량:
5.14M
Relative Volume:
1.12
시가총액:
$1.29B
수익:
$45.97M
순이익/손실:
$-508.80M
주가수익비율:
-2.2007
EPS:
-5.48
순현금흐름:
$-382.65M
1주 성능:
+6.21%
1개월 성능:
+4.15%
6개월 성능:
+28.78%
1년 성능:
-42.38%
1일 변동 폭
$11.63
$12.23
1주일 범위
$11.06
$12.46
52주 변동 폭
$5.90
$23.76
Intellia Therapeutics Inc Stock (NTLA) Company Profile
명칭
Intellia Therapeutics Inc
전화
857-285-6200
주소
40 ERIE STREET, CAMBRIDGE, MA
NTLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
12.06 | 1.25B | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-21 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | 개시 | H.C. Wainwright | Buy |
| 2025-02-28 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-02-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-04-13 | 개시 | Canaccord Genuity | Buy |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-03-14 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-24 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-01-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-01 | 개시 | Citigroup | Sell |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-06-16 | 개시 | BofA Securities | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-02-18 | 개시 | William Blair | Outperform |
| 2022-02-07 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-31 | 개시 | Cowen | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
| 2021-10-05 | 개시 | Guggenheim | Buy |
| 2021-09-24 | 개시 | Stifel | Buy |
| 2021-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-11 | 개시 | H.C. Wainwright | Buy |
| 2021-05-07 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | 개시 | Truist | Buy |
| 2020-10-14 | 개시 | Wells Fargo | Overweight |
| 2020-09-18 | 개시 | Goldman | Buy |
| 2020-02-28 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-02-14 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-11-01 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | 개시 | Robert W. Baird | Outperform |
| 2019-06-10 | 개시 | ROTH Capital | Neutral |
| 2019-05-03 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-11-02 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-10-29 | 개시 | Credit Suisse | Neutral |
| 2018-09-21 | 개시 | Raymond James | Mkt Perform |
| 2018-05-15 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | 개시 | JMP Securities | Mkt Outperform |
| 2017-11-01 | 재확인 | Jefferies | Buy |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-05 | 업그레이드 | Jefferies | Hold → Buy |
모두보기
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
Real time alert setup for Intellia Therapeutics Inc. performanceJuly 2025 Momentum & Reliable Intraday Trade Plans - Newser
Using data tools to time your Intellia Therapeutics Inc. exitEarnings Overview Report & AI Forecasted Entry and Exit Points - Newser
Signal strength of Intellia Therapeutics Inc. stock in tech scannersQuarterly Trade Summary & Free Verified High Yield Trade Plans - Newser
Is Intellia Therapeutics Inc. stock a smart retirement pickJuly 2025 Gainers & Safe Entry Momentum Stock Tips - خودرو بانک
What’s next for Intellia Therapeutics Inc. stockMarket Weekly Review & Daily Profit Maximizing Trade Tips - خودرو بانک
Risk Check: Will Intellia Therapeutics Inc. outperform tech stocksQuarterly Portfolio Report & Free Low Drawdown Momentum Trade Ideas - خودرو بانک
Is Intellia Therapeutics Inc. benefiting from interest rate changes2025 Retail Activity & Stepwise Swing Trade Plans - خودرو بانک
Is Intellia Therapeutics Inc. building a consolidation basePortfolio Risk Summary & Long-Term Safe Investment Plans - Newser
How hedge fund analytics apply to Intellia Therapeutics Inc. stockTrade Exit Report & Safe Entry Zone Identification - Newser
Will Intellia Therapeutics Inc. stock hit new highs in YEARGlobal Markets & Weekly High Momentum Picks - خودرو بانک
Chart based analysis of Intellia Therapeutics Inc. trendsTrend Reversal & Stepwise Trade Execution Plans - Newser
Published on: 2025-09-05 05:28:03 - Newser
Chart based exit strategy for Intellia Therapeutics Inc.July 2025 Market Mood & Real-Time Stock Movement Alerts - Newser
How to forecast Intellia Therapeutics Inc. trends using time series2025 Price Targets & Free Technical Confirmation Trade Alerts - Newser
Pattern recognition hints at Intellia Therapeutics Inc. upsideLayoff News & Smart Allocation Stock Reports - Newser
ARK Investment Expands Stake in Intellia Therapeutics (NTLA) - GuruFocus
Published on: 2025-09-04 03:41:57 - Newser
Multi asset correlation models including Intellia Therapeutics Inc.2025 Retail Activity & Stepwise Trade Signal Implementation - Newser
Why Intellia Therapeutics Inc. is moving todayTrade Volume Summary & Reliable Volume Spike Trade Alerts - Newser
Is Intellia Therapeutics Inc. stock reversal real or fakeCEO Change & Consistent Profit Trade Alerts - Newser
Cathie Wood’s ARK ETF adjusts portfolio, sells Roku stock, buys CRISPR and Intellia - Investing.com
Panic Selling: Is Intellia Therapeutics Inc. benefiting from interest rate changesJuly 2025 Drop Watch & Verified High Yield Trade Plans - خودرو بانک
Does Intellia Therapeutics Inc. stock have upside surprise potentialJuly 2025 Big Picture & Real-Time Buy Zone Alerts - خودرو بانک
Intellia Therapeutics Inc. stock outlook for YEARPortfolio Growth Summary & Weekly Sector Rotation Insights - Newser
Leading vs lagging indicators on Intellia Therapeutics Inc. performanceWall Street Watch & Fast Gaining Stock Strategy Reports - Newser
What the charts say about Intellia Therapeutics Inc. todayPortfolio Value Report & Stepwise Swing Trade Plans - Newser
Tools to assess Intellia Therapeutics Inc.’s risk profileQuarterly Trade Report & Expert Verified Stock Movement Alerts - Newser
Merger Talk: Is Intellia Therapeutics Inc. benefiting from interest rate changesEarnings Performance Report & Stepwise Trade Signal Implementation - خودرو بانک
Will Intellia Therapeutics Inc. outperform tech stocksMarket Activity Report & Technical Buy Zone Confirmation - خودرو بانک
Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus - Nasdaq
Gene Editing Market to Surpass USD 15.46 Billion by 2032, Fueled by Breakthroughs in CRISPR Technology and Precision Medicine – SNS Insider - GlobeNewswire Inc.
Intellia Therapeutics Inc. Stock Flags Risk Zone in Volatility Index getLinesFromResByArray error: size == 0 - thegnnews.com
Aug Levels: What’s next for Intellia Therapeutics Inc. stockInsider Selling & Short-Term Trading Opportunity Alerts - خودرو بانک
Why is Intellia Therapeutics Inc. stock going upJuly 2025 Update & High Accuracy Trade Signal Alerts - خودرو بانک
Is Intellia Therapeutics Inc. stock good for income investorsPortfolio Performance Report & Consistent Profit Trade Alerts - خودرو بانک
Insider Buy: Can Intellia Therapeutics Inc. navigate macro headwindsWeekly Trade Recap & Weekly Top Performers Watchlists - خودرو بانک
Why big players are pouring millions in THIS biotech stock - TradingView
Key metrics from Intellia Therapeutics Inc.’s quarterly dataJuly 2025 EndofMonth & Risk Controlled Daily Trade Plans - Newser
Intellia Therapeutics Inc. stock chart pattern explainedJuly 2025 Review & Weekly High Potential Stock Alerts - Newser
Applying sector rotation models to Intellia Therapeutics Inc.Trade Entry Report & Fast Entry High Yield Stock Tips - Newser
Intellia Therapeutics Inc. stock prediction for this week2025 Investor Takeaways & High Accuracy Swing Entry Alerts - Newser
Using Python tools to backtest Intellia Therapeutics Inc. strategiesJuly 2025 Breakouts & AI Powered Market Trend Analysis - Newser
Intellia Therapeutics Inc (NTLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Intellia Therapeutics Inc 주식 (NTLA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Dulac Edward J III | EVP, Chief Financial Officer |
Jul 23 '25 |
Sale |
14.02 |
7,462 |
104,617 |
106,062 |
| Clark Eliana | EVP, Chief Technical Officer |
Jul 01 '25 |
Sale |
9.82 |
1,022 |
10,036 |
95,369 |
| Dube Michael P | VP, Chief Accounting Officer |
Jul 02 '25 |
Sale |
9.95 |
2,503 |
24,905 |
57,137 |
| GOODMAN JESSE | Director |
Jun 30 '25 |
Sale |
9.56 |
1,547 |
14,789 |
25,906 |
| GOODMAN JESSE | Director |
Jul 01 '25 |
Sale |
9.23 |
1,547 |
14,279 |
24,359 |
| Bhanji Muna | Director |
Apr 29 '25 |
Sale |
8.50 |
265 |
2,252 |
19,203 |
| Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '25 |
Sale |
8.99 |
679 |
6,104 |
95,369 |
| BASTA JAMES | EVP, General Counsel |
Mar 04 '25 |
Sale |
8.99 |
2,572 |
23,122 |
111,925 |
| Bhanji Muna | Director |
Jan 29 '25 |
Sale |
9.97 |
265 |
2,642 |
19,468 |
| Dube Michael P | VP, Chief Accounting Officer |
Jan 03 '25 |
Sale |
12.18 |
1,372 |
16,711 |
45,640 |
1.40%
자본화:
|
볼륨(24시간):